Patents by Inventor Samuel Zalipsky

Samuel Zalipsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030215490
    Abstract: Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate.
    Type: Application
    Filed: April 2, 2002
    Publication date: November 20, 2003
    Applicant: Sequus Pharmaceuticals, Inc.
    Inventors: Theresa M. Allen, Paul Steven Uster, Francis J. Martin, Samuel Zalipsky
  • Publication number: 20030211079
    Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
    Type: Application
    Filed: February 21, 2003
    Publication date: November 13, 2003
    Applicant: Alza Corporation
    Inventor: Samuel Zalipsky
  • Publication number: 20030198665
    Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
    Type: Application
    Filed: May 14, 2003
    Publication date: October 23, 2003
    Applicant: Alza Corporation
    Inventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz, Herve Bercovier
  • Patent number: 6605299
    Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: August 12, 2003
    Assignee: Alza Corporation
    Inventor: Samuel Zalipsky
  • Patent number: 6586001
    Abstract: Liposomes containing PEG-substituted neutral lipopolymers provide similar circulation times to liposomes incorporating conventional, negatively charged PEG-substituted phospholipids. Use of the uncharged lipopolymers can also present advantages in terms of interactions with cell surfaces and reduced leakage of charged substances, particularly cationic drugs, from the liposomes. The lipopolymers are of the formula: wherein each of R1 and R2 is an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms, n is about 10 to about 300, Z is selected from the group consisting of hydroxy, alkoxy, benzyloxy, carboxylic ester, sulfonic ester, alkyl or aryl carbonate, amino, and alkylamino, and the linkage L is selected from the group consisting of (i) —X—(C═O)—Y—CH2—, (ii) —X—(C═O)—, and (iii) —X—CH2—, wherein X and Y are independently selected from oxygen, NH, and a direct linkage.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: July 1, 2003
    Assignee: Alza Corporation
    Inventor: Samuel Zalipsky
  • Patent number: 6586002
    Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 1, 2003
    Assignee: Alza Corporation
    Inventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz, Herve Bercovier
  • Publication number: 20030054028
    Abstract: Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.
    Type: Application
    Filed: January 25, 2002
    Publication date: March 20, 2003
    Applicant: Alza Corporation
    Inventors: Samuel Zalipsky, Alberto A. Gabizon
  • Publication number: 20030031704
    Abstract: A liposome composition for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiologic pH and (ii) a lipid joined to a hydrophilic polymer by a dithiobenzyl linkage. The liposomes are associated with a nucleic acid for delievery to a cell.
    Type: Application
    Filed: December 12, 2001
    Publication date: February 13, 2003
    Applicant: Alza Corporation
    Inventors: Shi-Kun Huang, Samuel Zalipsky, Wei-Ming Zhang
  • Publication number: 20020192275
    Abstract: A liposomal composition and a method of using the same for achieving intracellular delivery of a liposome-entrapped agent is described. The liposomes are composed of a pH sensitive lipid and include a targeting ligand to direct the liposomes to a target cell. The liposomes also include a stabilizing component, such a polymer-derivatized lipid, where the polymer is attached to the lipid by a releasable linkage. Administration of the liposomes results in cellular internalization and destabilization of the liposome for intracellular delivery of the entrapped agent.
    Type: Application
    Filed: March 26, 2002
    Publication date: December 19, 2002
    Inventors: Samuel Zalipsky, Theresa M. Allen, Shi Kun Huang
  • Publication number: 20020172711
    Abstract: A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposome outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a method for using the composition to deliver a compound to target cells, and a method for selecting suitable hydrophobic polymers for use in the composition.
    Type: Application
    Filed: December 10, 2001
    Publication date: November 21, 2002
    Applicant: Alza Corporation
    Inventors: Francis J. Martin, Samuel Zalipsky
  • Publication number: 20020128195
    Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
    Type: Application
    Filed: October 15, 2001
    Publication date: September 12, 2002
    Applicant: Alza Corporation
    Inventor: Samuel Zalipsky
  • Publication number: 20020102733
    Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.
    Type: Application
    Filed: February 10, 2000
    Publication date: August 1, 2002
    Inventors: Francis J. Martin, Samuel Zalipsky, Shi Kun Huang
  • Patent number: 6365179
    Abstract: Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: April 2, 2002
    Assignee: ALZA Corporation
    Inventors: Samuel Zalipsky, Alberto A. Gabizon
  • Patent number: 6342244
    Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: January 29, 2002
    Assignee: Alza Corporation
    Inventor: Samuel Zalipsky
  • Patent number: 6326353
    Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
    Type: Grant
    Filed: March 23, 1993
    Date of Patent: December 4, 2001
    Assignee: Sequus Pharmaceuticals, Inc.
    Inventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz
  • Publication number: 20010043929
    Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
    Type: Application
    Filed: June 8, 2001
    Publication date: November 22, 2001
    Applicant: Alza Corporation
    Inventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz, Herve Bercovier
  • Patent number: 6316024
    Abstract: Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: November 13, 2001
    Assignee: Sequus Pharmaceuticals, Inc.
    Inventors: Theresa M. Allen, Paul Uster, Francis J. Martin, Samuel Zalipsky
  • Publication number: 20010038851
    Abstract: Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate.
    Type: Application
    Filed: June 7, 2001
    Publication date: November 8, 2001
    Applicant: Alza Corporation
    Inventors: Theresa M. Allen, Paul Uster, Francis J. Martin, Samuel Zalipsky
  • Patent number: 6224903
    Abstract: A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposome outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a polymer-lipid conjugate for use in promoting fusion between target membranes. The conjugate is composed of a first segment composed of a hydrophilic polymer and a second hydrophobic polymer segment. The second segment is joined to the first segment by a bond effective to release the first segment in response to an existing or an induced physiologic condition. Attached to the second segment is a vesicle-forming lipid member.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: May 1, 2001
    Assignee: Sequus Pharmaceuticals, Inc.
    Inventors: Francis J. Martin, Samuel Zalipsky
  • Patent number: 6180134
    Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 30, 2001
    Assignee: Sequus Pharmaceuticals, Inc.
    Inventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz